Literature DB >> 82084

Colonic bacterial activity, biliary cholesterol saturation, and pathogenesis of gallstones.

T S Low-Beer, S Nutter.   

Abstract

The relation between colonic bacterial metabolites in bile and saturation of bile with cholesterol was investigated. Eleven healthy men ingested metronidazole (2 g daily) for 10 days to inhibit anaerobic bacterial activity. Bile composition was determined in fasting samples aspirated from the duodenum before metronidazole was given, at the end of 10 days on metronidazole, and a month after the drug was discontinued. Bile cholesterol saturation fell in ten of the eleven subjects from a mean of 1.00 to 0.83 and rose in all eleven after the drug was stopped. At the same time the proportion of deoxycholate in bile acid decreased from a mean of 24% to 7%, returning to 22% of the total a month after metronidazole had been stopped, and the proportion of chenodeoxycholate changed significantly from 33% to 46% and back to 33%. There was little change in cholate concentrations. Deoxycholate is formed exclusively by bacterial action in the colon. Its administration increases cholesterol saturation of bile, while chenodeoxycholate reduces it. These results suggest that colonic function is important in regulating bile composition. Dietary measures which reduce the return of newly formed deoxycholate from the colon to the bile reduce cholesterol saturation and so are likely to reduce the risk of gallstones.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 82084     DOI: 10.1016/s0140-6736(78)91800-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  Bile salt hydrolase activity in probiotics.

Authors:  Máire Begley; Colin Hill; Cormac G M Gahan
Journal:  Appl Environ Microbiol       Date:  2006-03       Impact factor: 4.792

2.  Molecular cloning of a gene encoding a 45,000-dalton polypeptide associated with bile acid 7-dehydroxylation in Eubacterium sp. strain VPI 12708.

Authors:  W B White; J P Coleman; P B Hylemon
Journal:  J Bacteriol       Date:  1988-02       Impact factor: 3.490

3.  Interdigestive gallbladder emptying, antroduodenal motility, and motilin release patterns are altered in cholesterol gallstone patients.

Authors:  M F Stolk; K J Van Erpecum; T L Peeters; M Samsom; A J Smout; L M Akkermans; G P Vanberge-Henegouwen
Journal:  Dig Dis Sci       Date:  2001-06       Impact factor: 3.199

Review 4.  Update on the Molecular Mechanisms Underlying the Effect of Cholecystokinin and Cholecystokinin-1 Receptor on the Formation of Cholesterol Gallstones.

Authors:  Helen H Wang; Piero Portincasa; David Q-H Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

5.  Evidence for a multigene family involved in bile acid 7-dehydroxylation in Eubacterium sp. strain VPI 12708.

Authors:  W B White; C V Franklund; J P Coleman; P B Hylemon
Journal:  J Bacteriol       Date:  1988-10       Impact factor: 3.490

Review 6.  Deoxycholic acid and the pathogenesis of gall stones.

Authors:  S N Marcus; K W Heaton
Journal:  Gut       Date:  1988-04       Impact factor: 23.059

7.  Effects of the fibre components pectin, cellulose, and lignin on bile salt metabolism and biliary lipid composition in man.

Authors:  L C Hillman; S G Peters; C A Fisher; E W Pomare
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

8.  Deoxycholic acid in gall bladder bile does not account for the shortened nucleation time in patients with cholesterol gall stones.

Authors:  H Noshiro; K Chijiiwa; I Makino; K Nakano; I Hirota
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

9.  Molecular cloning of bile acid 7-dehydroxylase from Eubacterium sp. strain VPI 12708.

Authors:  J P Coleman; W B White; P B Hylemon
Journal:  J Bacteriol       Date:  1987-04       Impact factor: 3.490

10.  Effect of small doses of deoxycholic acid on bile cholesterol saturation in patients with liver cirrhosis.

Authors:  P Di Donato; F Carubbi; M Ponz de Leon; N Carulli
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.